EBV-Transformed B Cell Lines for Human Antibody Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing therapeutic monoclonal antibodies from human sources are biologically and technically challenging, particularly in generating affinity-matured antibodies, as they often require laborious screening and extensive processes, and existing methods like human hybridomas and transgenic mice are inefficient or not commonly available.
Innovation Solution
A method involving obtaining a polynucleotide library from B cells, where each polynucleotide comprises an expressed B cell variable immunoglobulin region coupled with a distinct identification region, allowing for the production of affinity-matured human antibodies without the need for extensive screening or humanization, and applicable in various research areas.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If human hybridomas are used to produce therapeutic monoclonal antibodies, then human antibodies can be generated, but the process is biologically and technically challenging with low efficiency and spontaneous loss of antibody genes
Solution Approach 1:
The patent uses EBV-transformed B-cell lines as an intermediary system instead of traditional human hybridomas. The EBV transformation immortalizes B cells while maintaining their ability to produce human antibodies, serving as a stable intermediary that avoids the instability and low efficiency of human hybridoma generation while preserving human antibody production capability
Solution Approach 2:
The patent transforms the biological parameters of B cells through EBV transformation, changing them from transient, culture-limited cells into immortalized, stable cell lines. This parameter change (from finite lifespan to indefinite proliferation) resolves the contradiction by maintaining antibody gene stability over prolonged culture periods while enabling high productivity through continuous antibody production
2Duration of action of stationary object
If EBV transformation is used to immortalize B cells, then antibody production can be maintained, but only extremely small fractions of cells are affinity matured or recognize the target antigen
Solution Approach 1:
The patent performs preliminary enrichment of antigen-specific B cells before EBV transformation by using antigen-specific sorting or selection methods. This preliminary action ensures that the immortalized cell lines are derived from antigen-specific precursors, guaranteeing that the resulting cell lines both produce human antibodies and recognize the target antigen with high frequency
Solution Approach 2:
The patent creates multiple independent EBV-transformed cell lines from different antigen-specific B cells, generating a library of cell lines that can be screened. This copying approach increases the probability of obtaining affinity-matured, antigen-specific cell lines while maintaining the cultural longevity provided by EBV transformation
3Productivity
If phage display libraries are used to produce human antibodies, then large numbers of antibodies can be screened, but the antibodies produced have low affinity and avidity without affinity maturation
Solution Approach 1:
The patent establishes continuous antibody production in immortalized EBV-transformed B-cell lines, eliminating the need for repeated phage display screening and affinity maturation cycles. The continuous culture system maintains high productivity while naturally selecting for high-affinity antibodies through in vivo affinity maturation that occurred in the original B cells
Solution Approach 2:
The patent replaces the expensive, labor-intensive phage display library system with a simpler, more economical approach using immortalized B-cell lines. Instead of continuously generating and screening large phage libraries, the system uses readily available EBV-transformed cell lines that provide both high productivity and high affinity antibodies at lower cost and complexity
4Manufacturing precision
If transgenic mice with human antibody repertoire are used, then affinity-matured human antibodies can be produced, but such mice are proprietary and not commonly available
Solution Approach 1:
The patent uses human B cells that naturally undergo affinity maturation in vivo, eliminating the need for transgenic mice with human antibody repertoires. The human B cells themselves perform the affinity maturation function through normal immune responses, making the system self-sufficient and widely available without requiring proprietary transgenic animal models
Data Source
Figure 1
Figure 2(a)~2(c)
Figure 3(a)~3(c)
AI summary
Disclosed herein are compositions and methods for sequencing, analyzing, and utilizing samples such as single samples. Also disclosed herein are compositions and methods for matching together two or more sequences from a sample. Also disclosed herien are compositions and methods for expressing and screening molecules of interest.